688373 Stock Overview
A biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Shanghai MicuRx Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥3.90 |
52 Week High | CN¥8.27 |
52 Week Low | CN¥3.23 |
Beta | 0.64 |
11 Month Change | 2.63% |
3 Month Change | -6.92% |
1 Year Change | -44.13% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -64.15% |
Recent News & Updates
Shareholder Returns
688373 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 3.4% | 2.4% | 5.4% |
1Y | -44.1% | -27.2% | -16.2% |
Return vs Industry: 688373 underperformed the CN Biotechs industry which returned -27.2% over the past year.
Return vs Market: 688373 underperformed the CN Market which returned -16.2% over the past year.
Price Volatility
688373 volatility | |
---|---|
688373 Average Weekly Movement | 5.6% |
Biotechs Industry Average Movement | 5.7% |
Market Average Movement | 5.4% |
10% most volatile stocks in CN Market | 8.4% |
10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 688373 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688373's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 188 | Yuan Zhengyu | www.micurxchina.com |
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. Shanghai MicuRx Pharmaceutical Co., Ltd.
Shanghai MicuRx Pharmaceutical Co., Ltd. Fundamentals Summary
688373 fundamental statistics | |
---|---|
Market cap | CN¥2.53b |
Earnings (TTM) | -CN¥497.31m |
Revenue (TTM) | CN¥109.40m |
23.4x
P/S Ratio-5.1x
P/E RatioIs 688373 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688373 income statement (TTM) | |
---|---|
Revenue | CN¥109.40m |
Cost of Revenue | CN¥20.06m |
Gross Profit | CN¥89.34m |
Other Expenses | CN¥586.65m |
Earnings | -CN¥497.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.76 |
Gross Margin | 81.66% |
Net Profit Margin | -454.56% |
Debt/Equity Ratio | 27.8% |
How did 688373 perform over the long term?
See historical performance and comparison